戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ge of the gamma-glutamyl bond and release of cysteinylglycine.
2 ne, releasing glutamic acid or glutamine and cysteinylglycine.
3 tubules perfused with mercuric conjugates of cysteinylglycine.
4 se) to yield the S-benzfurazan derivative of cysteinylglycine.
5 rexpression also significantly lowered serum cysteinylglycine (3.6 versus 2.8 micromol/L; P<0.003) le
6                                              Cysteinylglycine, a prooxidant generated during the cata
7  thiol glutathione amide, gamma-L-glutamyl-L-cysteinylglycine amide (GASH), when grown photoheterotro
8 dditional four metabolites (22% of Tp dose): cysteinylglycine and cysteine derivatives of glutathione
9 served no overall association between plasma cysteinylglycine and invasive breast cancer risk.
10 thiols (glutathione, cysteine, homocysteine, cysteinylglycine, and beta-mercaptoethanol) and human se
11 sulted in significant increases in cysteine, cysteinylglycine, and glutathione concentrations (P < 0.
12 ne, glutamylcysteine, total glutathione, and cysteinylglycine; capillary electrophoresis) were collec
13 coli and shown to catalyze the hydrolysis of cysteinylglycine (Cys-Gly) with the same kinetics as the
14 ne, S-adenosylmethionine (AdoMet), cysteine, cysteinylglycine (cys-gly), and glutathione (GSH) were m
15 thione, vitamin B-6, homocysteine, cysteine, cysteinylglycine (CysGly), and glutamylcysteine (GluCys)
16 e metabolism was heavily represented, with L-cysteinylglycine disulfide showing the strongest associa
17            The tripeptide gamma-L-glutamyl-L-cysteinylglycine (glutathione) is one of the major antio
18  binding properties of 5 different peptides (cysteinylglycine, glutathione, Cys-Ile-His-Asn-Pro, Cys-
19 oding the first enzyme in gamma-l-glutamyl-l-cysteinylglycine (GSH) biosynthesis, cannot grow in its
20 fluid (ELF), glutathione (L-alpha-glutamyl-L-cysteinylglycine, GSH) is essential for adequate protect
21 racterization of glutathione (gamma-glutamyl-cysteinylglycine, GSH)-trapped reactive metabolites usin
22 ng strategy targeting (i) glutathione-, (ii) cysteinylglycine-, (iii) cysteine-, and (iv) mercapturic
23 glutathione (GSH), cysteine, methionine, and cysteinylglycine in liver.
24                                              Cysteinylglycine is a pro-oxidant metabolite of glutathi
25            We prospectively evaluated plasma cysteinylglycine levels and invasive breast cancer risk
26                              However, higher cysteinylglycine levels were marginally associated with
27 glycyl-(S-4-nitrobenzo-2-oxa- 1,3-diazole)-L-cysteinylglycine [NO2ZGly(S-NBD)CysGly] with an absorpti
28 en mercuric conjugates of glutathione (GSH), cysteinylglycine or cysteine (containing 203Hg2+) were p
29  than in the form of a mercuric conjugate of cysteinylglycine or GSH.
30 st structures of any eukaryotic GGT with the cysteinylglycine region of the substrate-binding site oc
31       Women in the highest quintile group of cysteinylglycine relative to the lowest group had multiv
32 e and cysteinylglycine to cystine and bis(-S-cysteinylglycine), respectively.
33                  Observational data relating cysteinylglycine status to breast cancer risk are lackin
34 t catalyst for the oxidation of cysteine and cysteinylglycine to cystine and bis(-S-cysteinylglycine)
35                                        Serum cysteinylglycine was inversely associated with adenocarc
36                            Both cysteine and cysteinylglycine were not associated with esophageal squ
37 d fish, PAHs conjugated with glutathione and cysteinylglycine were uncovered.
38 rved associations between serum cysteine and cysteinylglycine with upper gastrointestinal cancer risk